United States· US:47335-108_606e15f1-063b-40c2-84a3-142272020d64
LEQSELVI
A deuruxolitinib product containing deuruxolitinib phosphate, registered in United States by Sun Pharmaceutical Industries, Inc..
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- DEURUXOLITINIB PHOSPHATE
- Manufacturer
- Sun Pharmaceutical Industries, Inc.
- Country
- United States (US)
- ATC code
- L04AF09
- ATC class
- Deuruxolitinib
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 1
- ndc1147335-108-86
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under L04AF09
Deuruxolitinib, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8d9fe703-043a-45ae-a41f-6fcf641970d1 GET /v1/drugs/8d9fe703-043a-45ae-a41f-6fcf641970d1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "8",
"substance": "DEURUXOLITINIB PHOSPHATE",
"productndc": "47335-108",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA217900",
"marketing_category": "NDA"
}See everything about deuruxolitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.